Bahl & Gaynor Inc. Sells 649 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Bahl & Gaynor Inc. trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 13.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,327 shares of the medical instruments supplier’s stock after selling 649 shares during the quarter. Bahl & Gaynor Inc.’s holdings in West Pharmaceutical Services were worth $1,425,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Evoke Wealth LLC acquired a new stake in West Pharmaceutical Services during the 4th quarter worth approximately $7,770,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of West Pharmaceutical Services by 1.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock worth $75,766,000 after purchasing an additional 2,759 shares during the period. Vanguard Group Inc. grew its stake in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after purchasing an additional 104,740 shares during the last quarter. Mizuho Markets Americas LLC increased its holdings in West Pharmaceutical Services by 142.3% in the first quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock valued at $11,724,000 after purchasing an additional 17,399 shares during the period. Finally, Hsbc Holdings PLC raised its position in West Pharmaceutical Services by 39.8% during the 4th quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock worth $48,750,000 after purchasing an additional 39,392 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Trading Down 1.6 %

NYSE WST opened at $297.48 on Friday. The firm has a market capitalization of $21.67 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 10.60 and a beta of 1.01. The business’s 50-day moving average price is $305.71 and its two-hundred day moving average price is $339.73. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.11 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares in the company, valued at approximately $443,400. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.